OpenDNA

Company Overview

Snapshot

Founded in September 2018 by Eran Feldhay and Erez Ornan, OpenDNA operates with 1–10 employees. The company has raised $2.45M across 5 funding rounds and secured additional non-equity grants. In November 2023, OpenDNA partnered with PartnerMD to integrate its AI-based genetic risk testing for cardiometabolic diseases.

Business overview

OpenDNA develops an AI platform that integrates clinical and genomic data analysis to predict and prevent polygenic diseases. The platform enables healthcare providers and payers to apply genomic precision medicine and population genomics approaches, utilizing prediction models to identify high-risk patients and inform targeted prevention strategies. Initially focused on cardiometabolic syndrome, OpenDNA plans to expand its technology to other complex polygenic disease states, including cancer, chronic kidney failure, and autoimmune, neurological, and musculoskeletal diseases. The company operates within the Digital Healthcare sector, specifically in Medical Decision Support, leveraging Artificial Intelligence and Genes technologies, and serves healthcare providers and insurance companies in the United States and Europe.

Strategic signal

OpenDNA's partnership with PartnerMD in November 2023 to provide AI-based genetic risk testing for cardiometabolic diseases signals a significant step in commercializing its precision genomic AI platform. This collaboration validates the company's technology for real-world clinical application and demonstrates its ability to integrate with established healthcare providers, indicating a strong potential for market penetration and impact on preventive medicine.

Company Intelligence Q&A

What is OpenDNA's primary focus?

OpenDNA focuses on using Precision Genomic AI to predict and prevent heart disease by combining clinical and genomic data analysis for polygenic diseases.

When was OpenDNA founded and by whom?

OpenDNA was founded in September 2018 by Eran Feldhay and Erez Ornan.

What was a key partnership announced by OpenDNA in late 2023?

In November 2023, OpenDNA partnered with PartnerMD to provide patients with AI-based genetic risk testing for cardiometabolic diseases.

What was the outcome of OpenDNA's clinical study in 2023?

In June 2023, OpenDNA announced the successful conclusion of a 150-patient clinical study.

What significant research agreement did OpenDNA announce in 2022?

In March 2022, OpenDNA announced a know-how and research agreement with Mayo Clinic as part of a pilot clinical study for cardiovascular disease prevention.